319 related articles for article (PubMed ID: 10436809)
1. Role of tumour markers, cytogenetics.
Lamerz R
Ann Oncol; 1999; 10 Suppl 4():145-9. PubMed ID: 10436809
[TBL] [Abstract][Full Text] [Related]
2. CA 19-9: Biochemical and Clinical Aspects.
Scarà S; Bottoni P; Scatena R
Adv Exp Med Biol; 2015; 867():247-60. PubMed ID: 26530370
[TBL] [Abstract][Full Text] [Related]
3. Epitope analysis of SPan-1 and DUPAN-2 using synthesized glycoconjugates sialyllact-N-fucopentaose II and sialyllact-N-tetraose.
Kawa S; Tokoo M; Oguchi H; Furuta S; Homma T; Hasegawa Y; Ogata H; Sakata K
Pancreas; 1994 Nov; 9(6):692-7. PubMed ID: 7531332
[TBL] [Abstract][Full Text] [Related]
4. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of pancreatico-biliary malignancy: detection of gene mutations in plasma and stool.
Mulcahy H; Farthing MJ
Ann Oncol; 1999; 10 Suppl 4():114-7. PubMed ID: 10436800
[TBL] [Abstract][Full Text] [Related]
6. Sialyl-Tn, sialyl-Lewis Xi, CA 19-9, CA 125, carcinoembryonic antigen, and tissue polypeptide antigen in differentiating ovarian cancer from benign tumors.
Inoue M; Fujita M; Nakazawa A; Ogawa H; Tanizawa O
Obstet Gynecol; 1992 Mar; 79(3):434-40. PubMed ID: 1346716
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
8. Sialyl Lewis(a) ganglioside in pancreatic cancer tissue correlates with the serum CA 19-9 level.
Hamanaka Y; Hamanaka S; Suzuki M
Pancreas; 1996 Aug; 13(2):160-5. PubMed ID: 8829184
[TBL] [Abstract][Full Text] [Related]
9. [Clinical usefulness of tumor markers associated with pancreatic cancer].
Watanabe H; Kawakami H; Yamakawa O; Satomura Y; Ohta H; Motoo Y; Okai T; Sawabu N
Rinsho Byori; 1994 Feb; 42(2):127-38. PubMed ID: 7908065
[TBL] [Abstract][Full Text] [Related]
10. Preoperative hCGbeta and CA 72-4 are prognostic factors in gastric cancer.
Louhimo J; Kokkola A; Alfthan H; Stenman UH; Haglund C
Int J Cancer; 2004 Oct; 111(6):929-33. PubMed ID: 15300805
[TBL] [Abstract][Full Text] [Related]
11. Role of tumor markers and mutations in cells and pancreatic juice in the diagnosis of pancreatic cancer.
Tascilar M; Caspers E; Sturm PD; Goggins M; Hruban RH; Offerhaus GJ
Ann Oncol; 1999; 10 Suppl 4():107-10. PubMed ID: 10436798
[TBL] [Abstract][Full Text] [Related]
12. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
13. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
14. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping.
Luo G; Guo M; Jin K; Liu Z; Liu C; Cheng H; Lu Y; Long J; Liu L; Xu J; Ni Q; Yu X
Pancreatology; 2016; 16(6):1057-1062. PubMed ID: 27692554
[TBL] [Abstract][Full Text] [Related]
15. Expression of blood group-related antigens in normal and malignant pancreatic tissue correlated with genotype of the patient defined by saliva glycoprotein.
Ichihara T; Sakamoto J; Nakao A; Furukawa K; Watanabe T; Suzuki N; Horisawa M; Nagura H; Lloyd KO; Takagi H
Cancer; 1993 Jan; 71(1):71-81. PubMed ID: 8416729
[TBL] [Abstract][Full Text] [Related]
16. [Tumor markers--personal experience. The use of tumor markers for cancer of digestive organs].
Ishii M
Gan To Kagaku Ryoho; 1991 May; 18(6):1059-65. PubMed ID: 1709347
[TBL] [Abstract][Full Text] [Related]
17. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
[TBL] [Abstract][Full Text] [Related]
18. Molecular versus conventional markers in pancreatic cancer.
Friess H; Kleeff J; Gumbs A; Büchler MW
Digestion; 1997; 58(6):557-63. PubMed ID: 9438602
[TBL] [Abstract][Full Text] [Related]
19. Molecular oncology in pancreatic cancer.
Gansauge S; Gansauge F; Beger HG
J Mol Med (Berl); 1996 Jun; 74(6):313-20. PubMed ID: 8862512
[TBL] [Abstract][Full Text] [Related]
20. Carcinoembryonic antigen and blood group-related carbohydrate antigens in glycoproteins in human bile in hepatolithiasis. Japanese Study Group of Hepatolithiasis.
Sasaki M; Morita T; Hoso M; Nakanuma Y; Tanimura H
Hepatology; 1996 Feb; 23(2):258-63. PubMed ID: 8591850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
